Search

Author/Creator Cardoso, F

1. 121TiPKEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC). (13th May 2019)

Authors:
Cardoso, F; Jia, L; Hirshfield, K; Karantza, V
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 193OAn international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23) - EORTC QLQ-BR45. (23rd October 2018)

Authors:
Bjelic-Radisic, V; Bottomley, A; Cardoso, F; Cameron, D; Brain, E; Kuljanic, K; de Costa, R A; Conroy, T; Inwald, E; Serpentini, S; Pinto, M; Weis, J; Morag, O; Guro Lindviksmoen Astrup, G; Tomaszweksi, K; Pogoda, K; Sinai, P; Sprangers, M A G; Aaronson, N; Greimel, E
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 24TiPKEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer. (24th November 2019)

Authors:
Cardoso, F; Bardia, A; André, F; Cescon, D W; McArthur, H; Telli, M; Loi, S; Cortes, J; Schmid, P; Harbeck, N; Denkert, C; Jackisch, C; Jia, L; Hirshfield, K; Karantza, V
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 333PRibociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) who received prior chemotherapy (CT) for advanced disease: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018)

Authors:
Cardoso, F; Papazisis, K; De Laurentiis, M; Ring, A; Lu, J; Martín, M; Azim, H A; Zamagni, C; Zhou, K; Wu, J; Zarate, J P; Cottu, P H
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. (28th October 2017)

Authors:
Cardoso, F; Bartlett, J M S; Slaets, L; van Deurzen, C H M; van Leeuwen-Stok, E; Porter, P; Linderholm, B; Hedenfalk, I; Schröder, C; Martens, J; Bayani, J; van Asperen, C; Murray, M; Hudis, C; Middleton, L; Vermeij, J; Punie, K; Fraser, J; Nowaczyk, M; Rubio, I T
Journal:
Annals of oncology
Issue:
Volume 29:Number 2(2018)
Page Start:
405
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗